{"id":4203,"date":"2025-03-31T18:12:01","date_gmt":"2025-03-31T18:12:01","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/mitomycin-txt\/"},"modified":"2025-03-31T18:12:01","modified_gmt":"2025-03-31T18:12:01","slug":"mitomycin-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/mitomycin-txt\/","title":{"rendered":"Mitomycin.txt"},"content":{"rendered":"

CLINICAL USE <\/H3>
\nCytotoxic antibiotic used in a range of neoplastic conditions

DOSE IN NORMAL RENAL FUNCTION <\/H3>IV: 4\u201310 mg\/m2 or 0.06\u20130.15 mg\/kg given every 1\u20136 weeks, depending on concurrent therapy and bone marrow recoveryFor instillation into bladder: 20\u201340 mg

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :334.3<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :No data<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 10<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :0.5<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :50 minutes\/\u2013

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : 75% of normal dose

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR <10 mL\/min <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Antipsychotics: avoid concomitant use with clozapine (increased risk of agranulocytosis)

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>With water for injection or sodium chloride 0.9%; 5 mL for the 2 mg vial, at least 10 mL for the 10 mg vial and at least 20 mL for the 20 mg vial

    Route <\/H4>IV injection, intra-arterial, bladder instillation

    Rate of Administration <\/H4>Bolus injection over 3\u20135 minutes (1 mL\/ min)Infusion over 15\u201330 minutes

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>Prodrug, activated in vivo. Metabolism is predominantly in the liver. Rate of clearance is inversely proportional to the maximum serum concentration, due to saturation of the degradative pathways. Approximately 10% is excreted unchanged in the urine. Since metabolic pathways are saturated at low doses, the % dose excreted in the urine increases with increasing doseA syndrome of thrombotic microangiopathy resembling haemolytic-uraemic syndrome has been seen in patients receiving mitomycin, either alone or, more frequently, combined with other agents. Symptoms of haemolysis and renal failure may be accompanied by ATN and cardiovascular problems, pulmonary oedema and neurological symptomsPrincipal toxicity of mitomycin-C is bone marrow suppression. The nadir is usually around 4 weeks after treatment and toxicity is cumulative, with increasing risk after each course of treatment.
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Cytotoxic antibiotic used in a range of neoplastic<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4203","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4203"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4203\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4203"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4203"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}